Astepro Allergy is an allergy symptom reliever drug owned by Bayer Hlthcare. The active ingredient in the drug is azelastine hydrochloride. It was first authorized for market use on 17 June, 2021. The drug comes in the form of a metered nasal spray. Astepro Allergy is protected by 3 patents, none of which have yet expired.
The generic version of Astepro Allergy is expected to be available after 04 June, 2028. This is due to the expiry of the patent US8071073, titled 'Compositions comprising azelastine and methods of use thereof'.
Astepro Allergy is used over the counter for temporary relief of symptoms due to hay fever or other upper respiratory allergies. These symptoms may include nasal congestion, runny nose, sneezing, and an itchy nose. The effectiveness of the drug can be attributed to its active ingredient, azelastine hydrochloride.
Astepro Allergy has three patents. The last patent for Astepro Allergy, US8071073, is expected to expire on 04 June, 2028, hence enabling the release of Astepro Allergy generic. Below are the details of the patent: